Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.

You may also be interested in...



Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity

Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.

Teva’s New Copaxone Gaining Market Share Ahead Of Generics

With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.

Teva Ends Oncology, Women’s Health R&D Following Strategic Review

The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel